Jivi®, Newly Approved by FDA
On August 29, 2018, the FDA approved Jivi® (in clinical studies known as Antihemophilic Factor (Recombinant), PEGylated-aucl). Jivi® is indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.
Jivi® is available in four vial sizes of assay ranges: 500, 1000, 2000, and 3000 iu. If you are interested in Jivi®, ask your hematologist about it at your next hemophilia treatment center visit.